Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2021-09-20 Regulatory Filings
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Publication of data in glioblastoma cells
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's 'Reach' service, which is explicitly identified as a non-regulatory news distribution service. The content discusses the publication of academic research regarding the effectiveness of the company's drug candidate, SFX-01. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is a general corporate announcement regarding research developments, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous corporate announcements.
2021-09-20 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' for Evgen Pharma PLC. It explicitly details a change in voting rights held by a shareholder (James Robert Kight), crossing a specific threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2021-09-02 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for Evgen Pharma PLC. It is a market-related regulatory announcement concerning trading mechanics rather than a financial report, management update, or corporate action. As it does not fit into specific categories like M&A, dividends, or share issues, it falls under the general regulatory filing category.
2021-09-02 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's RNS (Regulatory News Service) regarding a 'Price Monitoring Extension' for Evgen Pharma PLC. It is a standard market operational notice rather than a financial report, management update, or corporate action. Since it does not fit into specific categories like dividends, share issues, or earnings, it falls under the general regulatory announcement category.
2021-09-02 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's RNS (Regulatory News Service) regarding a 'Second Price Monitoring Extension' for Evgen Pharma PLC. It is a standard market regulatory announcement concerning trading mechanics rather than a financial report, management update, or corporate action. As it does not fit into specific categories like M&A, dividends, or share issues, it falls under the general regulatory filing category.
2021-09-02 English
Glioma Orphan Drug designation granted by FDA
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Evgen Pharma plc. It details the company's receipt of Orphan Drug designation from the FDA for its product SFX-01. Since this is a general corporate announcement regarding regulatory/operational progress that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2021-09-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.